As of May 24, 2025, Sartorius Stedim Biotech SA (DIM.PA) reports a EV/EBITDA of 29.29.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Sartorius Stedim Biotech SA's EV/EBITDA to Peers
To better understand Sartorius Stedim Biotech SA's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Sartorius Stedim Biotech SA (DIM.PA) | 29.29 |
| Lonza Group AG (LONN.SW) | 39.89 |
| Chemometec A/S (CHEMM.CO) | 37.59 |
| Qiagen NV (QGEN) | 32.50 |
| Pcas SA (PCA.PA) | 27.22 |
| Bio-Techne Corp (TECH) | 27.13 |
Compared to its competitors, Sartorius Stedim Biotech SA's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.